Form 4: Akari Director Patel Boosts Stake via Warrants

Akari Therapeutics director and 10% owner Samir Patel acquired significant warrants and pre-funded warrants in a private placement and a note exchange agreement.

Summary

• Samir Patel, a director and 10% owner of Akari Therapeutics Plc, acquired derivative securities on December 16, 2025.
• This included 618,658 unregistered pre-funded warrants (PIPE PFWs) and 618,658 Series G Warrants through a private placement, at a combined purchase price of $0.4041 per unit.
• Additionally, Patel acquired 231,997 unregistered pre-funded warrants and 231,997 unregistered warrants through a note cancellation and exchange agreement, converting an unsecured promissory note.
• All these warrants and pre-funded warrants become exercisable upon shareholder approval.
• The Series G Warrants and Note Exchange Unregistered Warrants have a five-year term from approval, while the pre-funded warrants remain exercisable until fully exercised.
• The exercise price for the Series G Warrants and Note Exchange Unregistered Warrants is $0.3883 per American Depositary Share (ADS), and for the pre-funded warrants, it is $0.00001 per ADS.
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of warrants by a director and 10% owner indicates insider confidence. However, the future dilution potential and the contingency of shareholder approval introduce some uncertainty.

Positives

• Increased beneficial ownership by a director and 10% owner, signaling potential confidence in the company's future prospects.
• Conversion of an unsecured promissory note into equity-linked instruments reduces debt on the balance sheet, albeit with future dilution potential.

Negatives

• The issuance of a substantial number of warrants and pre-funded warrants introduces potential future dilution for existing shareholders upon exercise.
• Exercisability of all acquired warrants is contingent upon shareholder approval, introducing an element of uncertainty.

Risks

• Shareholder Dilution: The exercise of 618,658 PIPE PFWs, 618,658 Series G Warrants, 231,997 Note Exchange Unregistered Pre-Funded Warrants, and 231,997 Note Exchange Unregistered Warrants will dilute existing shareholders.
• Shareholder Approval Contingency: The exercisability of all acquired warrants is subject to shareholder approval, which is not guaranteed.
• Warrant Expiration: Warrants have expiration dates (five years for some, until fully exercised for others), and if the stock price does not exceed the exercise price, they may expire unexercised, potentially limiting the capital raised or debt converted.

Future Outlook

The exercisability of the acquired warrants and pre-funded warrants is contingent on future shareholder approval. The Series G Warrants and Note Exchange Unregistered Warrants have a five-year term from approval, while the pre-funded warrants remain exercisable until fully exercised.

Industry Context

This type of transaction (private placement of warrants, debt-to-equity conversion) is common for smaller biotechnology companies like Akari Therapeutics Plc to raise capital or restructure debt, often involving existing significant shareholders or insiders.

Corporate Governance

Related Party Transactions

• The private placement of warrants and pre-funded warrants involved Samir Patel, a director and 10% owner of Akari Therapeutics Plc.
• The note cancellation and exchange agreement involved Samir Patel, converting an unsecured promissory note held by him into equity-linked instruments.

Stakeholder Impact

• Shareholders: Potential for future dilution upon the exercise of the newly acquired warrants and pre-funded warrants. Shareholder approval is required for exercisability.
• Creditors: The conversion of an unsecured promissory note held by Samir Patel into equity-linked instruments reduces the company's outstanding debt to that specific creditor.

Next Steps

• Shareholder approval is required for the acquired warrants and pre-funded warrants to become exercisable.

Key Dates

Keywords

Akari Therapeutics, AKTX, Samir Patel, Form 4, insider transaction, warrants, pre-funded warrants, private placement, debt-to-equity, beneficial ownership, director, 10% owner